R
Richard J. Colonno
Researcher at Bristol-Myers Squibb
Publications - 146
Citations - 14924
Richard J. Colonno is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Entecavir & Hepatitis B virus. The author has an hindex of 57, co-authored 141 publications receiving 14236 citations. Previous affiliations of Richard J. Colonno include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients
Qi Huang,Bin Zhou,Bin Zhou,Dawei Cai,Yuhua Zong,Yaobo Wu,Shi Liu,Alexandre Mercier,Haitao Guo,Haitao Guo,Jinlin Hou,Richard J. Colonno,Jian Sun +12 more
TL;DR: Understanding the turnover time of preexisting cccDNA pools would be helpful in designing strategies to clear HBV by fully blocking the de novo generation of ccc DNA.
Journal ArticleDOI
Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase
Julie A. Lemm,Mengping Liu,Robert G. Gentles,Min Ding,Voss Stacey A,Lenore A. Pelosi,Ying-Kai Wang,Karen Rigat,Kathleen W. Mosure,Bender John A,Jay O. Knipe,Richard J. Colonno,Nicholas A. Meanwell,John F. Kadow,Kenneth S. Santone,Susan B. Roberts,Min Gao +16 more
TL;DR: BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase.
Journal ArticleDOI
Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.
Nicholas A. Meanwell,Owen Brendan Wallace,Haiquan Fang,Henry Wang,Milind Deshpande,Tao Wang,Zhiwei Yin,Zhongxing Zhang,Bradley C. Pearce,Jennifer James,Kap Sun Yeung,Zhilei Qiu,J. J. Kim Wright,Zheng Yang,Lisa Zadjura,Donald L. Tweedie,Suresh Yeola,Fang Zhao,Sunanda A. Ranadive,Brett A. Robinson,Yi Fei Gong,Hwei Gene Heidi Wang,Wade S. Blair,Pei Yong Shi,Richard J. Colonno,Pin fang Lin +25 more
TL;DR: A basic understanding of the indole element of the HIV attachment inhibitor pharmacophore is established and it is established that substitution at C-7 was readily tolerated and uniformly produced more potent HIV entry inhibitors.
Journal ArticleDOI
Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition
TL;DR: Cell culture and enzymatic studies yielded no evidence that would predict mitochondrial toxicity of ETV at exposure levels in excess of those expected to be achieved clinically, and combined treatments with NRTIs failed to result in cellular or mitochondrial toxicity.
Journal ArticleDOI
In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043
Nannan Zhou,Beata Nowicka-Sans,Sharon Zhang,Li Fan,Jie Fang,Hua Fang,Yi-Fei Gong,Betsy J. Eggers,David R. Langley,Tao Wang,John F. Kadow,Dennis M. Grasela,George J. Hanna,Louis Alexander,Richard J. Colonno,Mark Krystal,Pin-Fang Lin +16 more
TL;DR: It is demonstrated that although the majority of the subjects' viruses maintained sensitivity to BMS-488043, substitutions can be selected that decrease HIV-1 susceptibility to the AI, and therefore, attachment inhibitors could complement the current arsenal of anti-HIV agents.